Channel Medsystems Board Welcomes Heather Knight

Channel Medsystems Inc. has appointed Heather Knight to the company’s Board of Directors.
 
Knight is a medtech veteran with a track record of success in setting strategic direction and leading large, dynamic organizations. She has succeeded in building long-term, internal and external partnerships at all organizational levels. Knight is currently the Global Business Unit (GBU) president at Baxter Healthcare and is responsible for multiple GBUs in addition to commercial efforts across the Americas. She has led significant growth for these businesses including the Americas integration efforts of Hillrom, which Baxter acquired in 2021. Previously, Knight held various leadership roles at Covidien and then Medtronic plc, following its acquisition of Covidien.
 
“One in five women suffer from heavy menstrual bleeding (HMB)—but they shouldn’t have to,” said Knight. “I have closely followed Channel’s progress and development of the Cerene Cryotherapy Device for women with HMB. More women and their doctors need to know about their options, including the Cerene treatment which can be performed in the comfort and convenience of a doctor’s office. I look forward to contributing to this company dedicated to women’s healthcare, and to helping to drive awareness and adoption of its innovative solution for women with HMB.”
 
Cerene is an in-office endometrial cryoablation treatment that safely and effectively reduces heavy menstrual bleeding while naturally minimizing pain without requiring general anesthesia. The Cerene U.S. Food and Drug Administration pivotal clinical study (CLARITY), published in The Journal of Minimally Invasive Gynecology, concluded that 90% of all patients experienced an improvement in bleeding symptoms and were satisfied with the procedure at 12 months following treatment. Additionally, results published in The Journal of Minimally Invasive Gynecology in November 2021 demonstrated the use of cryoablation to treat the endometrium enabled the preservation of the uterine cavity, with visualization in 93% of evaluated patients, and the ability to evaluate for pathologic change in 96% of patients whose uterine cavities could be fully visualized. 
 
Berkeley, Calif.-based Channel Medsystems is a privately-held company that develops easy-to-use, safe, and cost-effective medical devices.